Albert David Limited
ALBERTDAVD.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.19B
Close$
$-53.54
106.9% downside
Current Fair Value
106.9% downsideOvervalued by 106.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.19 Billion |
|---|---|
| Enterprise Value | $6.19 Billion |
| Dividend Yield | $5.00 (0.63%) |
| Earnings per Share | $-2.62 |
| Beta | 0.29 |
| Outstanding Shares | 5,707,162 |
Return
| Return on Equity | 5.76% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 20.02 |
|---|---|
| PEG | 6.61 |
| Price to Sales | 1.22 |
| Price to Book Ratio | 1.14 |
| Enterprise Value to Revenue | 1.7 |
| Enterprise Value to EBIT | -62.62 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Albert David Ltd.
1,476 employees
CEO: Amit Mahla Albert David Ltd. is a pharmaceutical company that both produces and distributes a broad range of products, including finished drug formulations, intravenous solutions, herbal remedies, and bulk pharmaceutical ingredients. The company's ...